FDA approves Novartis' Itvisma, first gene therapy for SMA patients 2 and older
Source: SeekingAlpha
2025-11-25 04:39:25 ET
More on Novartis
- Novartis AG (NVS) Shareholder/Analyst Call Transcript
- Novartis AG (NVS) Shareholder/Analyst Call Transcript
- Novartis AG (NVS) Shareholder/Analyst Call - Slideshow
- Novartis projects 5–6% sales growth through 2030 as peak sales outlook for Kisqali, Scemblix increases
- Novartis to establish a manufacturing center in North Carolina
Read the full article on Seeking Alpha
For further details see:
FDA approves Novartis’ Itvisma, first gene therapy for SMA patients 2 and older
Novartis AG
NASDAQ: NVS
NVS Trading
0.24% G/L:
$143.7153 Last:
454,143 Volume:
$142.47 Open:
NVS Latest News
February 24, 2026 04:52:00 pm
Could Novartis Stock Quietly Help You Build a Millionaire Retirement Portfolio?
NVS Stock Data
$303,205,301,793
1,889,070,162
N/A
868
N/A
Pharmaceuticals
Healthcare
CH
Basel
